Niewinski and colleagues aimed to assess real-world use of daratumumab for patients with multiple myeloma and renal insufficiency. They performed a retrospective chart review of 101 patients ...

12 On the basis of these findings, daratumumab monotherapy at a dose of 16 mg per kilogram of body weight was approved by the Food and Drug Administration for the treatment of multiple myeloma in ...

Evaluated doses — based on the approved weekly 16-mg/kg IV dose for daratumumab — were 1,200 mg (n = 8; median age, 65.5 years) or 1,800 mg (n = 45; median age, 63 years). Treatment was ...

Patients in the daratumumab group received intravenous daratumumab at a dose of 16 mg per kilogram of body weight once weekly during cycles 1 and 2, every 2 weeks during cycles 3 through 6 ...

A retrospective chart review at the Mayo Clinic reviewed eligible patients with multiple myeloma or amyloid light-chain (AL) amyloidosis who received their first dose of daratumumab within the 4 ...

Treatment discontinuation due to a TEAE occurred in 5.7% of patients on daratumumab. Dose modifications were required for 46.6% of patients. Based on an earlier assessment of AQUILA, the developer ...

The FDA is likely to approve the first treatment for smoldering multiple myeloma but pass on a new option relapsed/refractory DLBCL, after votes by its Oncologic Drugs Advisory Committee.

The benefit of daratumumab was generally consistent across the study's prespecified subgroups, and the relative dose intensity of VRd was not affected by combination with daratumumab. In terms of ...

Daratumumab (Darzalex, Janssen) in combination with lenalidomide and dexamethasone is indicated for 'the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for ...

2.1 Daratumumab (Darzalex, Janssen) is indicated 'in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior ...